Physician profile
Thomas J Waliser
NPI 1639190572
$12,283.61
in general payments reported to CMS, 2019-2025
28 companies · $2,722 in 2025
The $2,722 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $83.58 · 2021: $7,002 · 2022: $349 · 2023: $562 · 2024: $177 · 2025: $2,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $1,404 · Travel and Lodging: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $1,403.91 |
| Travel and Lodging | $557.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,184.01 | 2021-2025 | Da Vinci Surgical System |
| Olympus America INC. | $494.33 | 2019-2025 | Olympus, Visera Elite II Video System Center Olympus Otv-S300, Olympus |
| Minerva Surgical, INC | $455.14 | 2019 | |
| Aegea Medical, INC. | $350.00 | 2019 | |
| Gynesonics, INC. | $312.11 | 2019-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbvie INC. | $195.50 | 2019-2022 | |
| Momentis Surgical INC. | $165.83 | 2021 | |
| Hologic Sales and Service, LLC | $159.36 | 2019-2022 | |
| Coopersurgical, INC. | $158.57 | 2019-2020 | |
| Channel Medsystems, INC. | $135.75 | 2023 | |
| Astellas Pharma US INC | $114.08 | 2024-2025 | Veozah |
| Ibsa Pharma INC. | $104.16 | 2023 | Tirosint |
| Monaghan Medical Corporation | $85.99 | 2023 | Aerobika |
| Coloplast Corp | $73.52 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.01 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $28.27 | 2019 | |
| Davol INC. | $26.28 | 2025 | Arista |
| Mayne Pharma Commercial LLC | $25.44 | 2023 | |
| Smith+Nephew, INC. | $22.63 | 2024 | Stravix Pl |
| Medtronic, INC. | $22.28 | 2022 | |
| Novo Nordisk INC | $18.05 | 2025 | Rybelsus, Ozempic |
| Aspira Women'S Health INC | $16.91 | 2024 | Ova1 |
| Sumitomo Pharma America, INC. | $15.73 | 2025 | Myfembree |
| Organon LLC | $15.23 | 2021 | |
| Boston Scientific Corporation | $14.08 | 2023 | Upsylon |
| Millicent US INC | $13.84 | 2019 | |
| Pfizer INC. | $13.29 | 2024 | |
| Merck Sharp & Dohme LLC | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Waliser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.